Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) Nexus 2018
Drug Market to See More Competition, Launch of Biosimilars in 2019
October 23, 2018
Dr Aimee Tharaldson Outlines Current Key Market Trends in Specialty Pharmacy
October 23, 2018
Dr Jane F. Barlow: How Curative, High-Cost Therapies Bring Challenges to the Reimbursement Landscape
October 23, 2018
Law to Curb Opioid Abuse Will Have Many Managed Care Priorities, Experts Say
October 23, 2018
Analysis Finds HIV Therapy Biktarvy Associated With Cost Savings Compared With Most Regimens
October 24, 2018
Dr Christopher Diehl Explains the Pharmacist's Role in Value-Based Models
October 24, 2018
Dr Jennifer Graff on Using Real-World Evidence to Deliver High-Quality Care
October 24, 2018
CMS Audits Give View Into How Well Health Plans Deliver Medicare Programs
October 24, 2018
Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS
October 25, 2018
Dan Mendelson: Healthcare Policy Changes Avalere Health Is Paying Attention To
October 25, 2018
Dr Kibum Kim on Precision Medicine in Managed Care
October 25, 2018
From Pathways to Pharmacy: Sharing Approaches to Value-Based Care
October 25, 2018
Currently Reading
Dr Jane F. Barlow on How Curative, High-Cost Therapies Will Affect Patient OOP Costs
November 09, 2018
Dan Mendelson Discusses How Mergers and Acquisitions Are Affecting the Market
November 14, 2018
Dan Mendelson on the Trump Administration's Efforts to Lower Drug Prices
November 22, 2018
Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies
November 27, 2018
Dan Mendelson's Expectations for Cross-Sector Mergers Like CVS, Aetna
November 28, 2018
Specialty Drug Approvals Dr Aimee Tharaldson is Looking Out for in 2019
November 29, 2018
Dan Mendelson on the Shift to Value-Based Care and Prescribing Patterns
December 22, 2018

Dr Jane F. Barlow on How Curative, High-Cost Therapies Will Affect Patient OOP Costs

Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket (OOP) costs and cost sharing.


Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket costs and cost sharing.

Transcript

How have curative, high-cost therapies impacted patient out-of-pocket costs and cost sharing?


Well, for most of these conditions, patients already have very high out-of-pocket costs. We’ve moved, in this country, to a lot of high-deductible plans and have high maximum out of pockets. So, most of these patients, I believe, will already meet their out-of-pocket maximum. So, whether they have an expensive treatment over time or they have one very high-cost treatment, I’m not sure it’s going to make a difference for the member in that year of treatment.

I think the real question is how does this sort of net out for them over time, is one piece, and whether their costs will be less in future years than it would have been if they were having other treatment or they had chronic costs. Or you know, the other question is, just the affordability in general. So, if patients choose not to get this new therapy because they just look at the overall cost and say it’s too much and they forgo therapy all together, that won’t be a good thing either. So, I think it’s a piece that has to be addressed, but it’s a broader issue than just the gene therapies.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up